Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Inventiva S.A.    IVA   FR0013233012

INVENTIVA S.A.

(IVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Inventiva S A : to participate at several investor conferences in October 2020

share with twitter share with LinkedIn share with facebook
09/24/2020 | 01:20pm EDT

Daix (France), September 24, 2020 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will participate to four investor conferences in October 2020.

Download PDF

Disclaimer

Inventiva SA published this content on 24 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2020 16:19:02 UTC


share with twitter share with LinkedIn share with facebook
All news about INVENTIVA S.A.
10/20INVENTIVA : receives FDA Fast Track designation in MPS VI for its clinical-stage..
AQ
10/19INVENTIVA S A : receives FDA Fast Track designation in MPS VI for its clinical-s..
PU
10/19INVENTIVA : receives FDA Fast Track designation in MPS VI for its clinical-stage..
AQ
10/19INVENTIVA : receives FDA Fast Track designation in MPS VI for its clinical-stage..
AQ
10/19INVENTIVA S A : receives FDA Fast Track designation in MPS VI for its clinical-s..
GL
10/19Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stag..
GL
10/13INVENTIVA : receives FDA Breakthrough Therapy designation for lead drug candidat..
AQ
10/13GLOBAL MARKETS LIVE: U.S. banks beat expectations
10/12INVENTIVA S A : receives FDA Breakthrough Therapy designation for lead drug cand..
PU
10/12INVENTIVA : receives FDA Breakthrough Therapy designation for lead drug candidat..
AQ
More news
Financials
Sales 2020 3,53 M 4,14 M 4,14 M
Net income 2020 -32,4 M -38,1 M -38,1 M
Net cash 2020 110 M 130 M 130 M
P/E ratio 2020 -9,82x
Yield 2020 -
Capitalization 379 M 446 M 445 M
EV / Sales 2020 76,2x
EV / Sales 2021 5,78x
Nbr of Employees 86
Free-Float 91,7%
Chart INVENTIVA S.A.
Duration : Period :
Inventiva S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA S.A.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 26,19 €
Last Close Price 9,88 €
Spread / Highest target 285%
Spread / Average Target 165%
Spread / Lowest Target 11,3%
EPS Revisions
Managers
NameTitle
Frédéric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Marie Paule Richard Chief Medical Officer
Chris Buyse Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVENTIVA S.A.169.21%446
GILEAD SCIENCES, INC.-7.65%75 236
REGENERON PHARMACEUTICALS50.42%61 299
VERTEX PHARMACEUTICALS-3.97%55 269
WUXI APPTEC CO., LTD.64.97%39 253
BEIGENE, LTD.81.31%27 327